Furthermore, targeting combinations such as IL-13Rα2 and EphA2 have been proposed to overcome tumor resistance and improve clinical response rates, showing particular promise in HER2-enriched and TNBC subtypes [35]. Here, ERBB2 is linked to neoplasm.